Back to medical news
ASCO Post
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
October 2, 2026
The source didn’t give us enough text to summarize this story. Use “Read original source” above to read it at ASCO Post.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
More medical news